Abstract
Graft-vs.-host disease (GVHD) can occur in cancer patients who receive blood products containing viable histoincompatible lymphocytes during a time when these patients are immunosuppressed from cancer therapy. Irradiation of all blood products prior to infusion obviates the problem. Doses of 1500-5000 rad (cGy) can be used without altering nonlymphocytic cellular function. Facts concerning the development of graft-vs.-host disease as well as guidelines for the irradiation of blood products for prevention of graft-vs.-host disease are presented and discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have